EMD: The Drug Pipeline Behind Emyria’s Psychedelic Clinics
Emyria is building a second business behind its growing mental health operation: a drug discovery and development programme focused on ...
Emyria is building a second business behind its growing mental health operation: a drug discovery and development programme focused on ...
Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
